XML 59 R49.htm IDEA: XBRL DOCUMENT v3.25.3
Segment Information (Details)
 3 Months Ended 9 Months Ended
Sep. 30, 2025
USD ($)
Jun. 30, 2025
USD ($)
Mar. 31, 2025
USD ($)
Sep. 30, 2024
USD ($)
Jun. 30, 2024
USD ($)
Mar. 31, 2024
USD ($)
Sep. 30, 2025
USD ($)
segment
Sep. 30, 2024
USD ($)
Segment Information                
Number of segments | segment             1  
Interest income $ 152,317     $ 135,430     $ 531,324 $ 205,576
Net loss (7,262,658) $ (6,220,058) $ (5,537,069) (12,638,357) $ (5,020,412) $ (1,066,947) (19,019,785) (18,725,716)
Other clinical costs                
Segment Information                
Program expenses related to clinical-stage product candidates             100,000  
Single reportable segment                
Segment Information                
Program expenses related to clinical-stage product candidates (4,799,800)     (1,078,604)     (11,595,094) (8,858,608)
Program expenses related to preclinical and discovery programs (119,507)     (200,759)     (333,746) (661,572)
Program expenses related to clinical manufacturing candidates (679,713)     (862,378)     (2,196,348) (3,487,187)
Personnel-related expenses (including stock-based compensation) (1,218,491)     (1,125,522)     (4,113,009) (4,666,720)
General and administrative professional and consultant fees (468,749)     (491,027)     (1,206,263) (1,250,575)
Other segment items (148,715)     (629,321)     (544,649) (1,035,394)
Interest income 152,317     135,430     531,324 205,576
Other non-cash income (expense) items 20,000     (8,386,176)     438,000 1,028,764
Net loss (7,262,658)     $ (12,638,357)     $ (19,019,785) $ (18,725,716)
Single reportable segment | AD 6 month trial                
Segment Information                
Program expenses related to clinical-stage product candidates (4,100,000)              
Single reportable segment | PD Open Label Extension study                
Segment Information                
Program expenses related to clinical-stage product candidates $ (700,000)